Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial of ZX-7101A Tablets to Evaluate the Efficacy and Safety in the Treatment of Uncomplicated Influenza in Adolescents

NCT06099873 is registered in ClinicalTrials.gov with Nanjing Zenshine Pharmaceuticals as lead sponsor.

NCT NCT06099873
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06099873 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial of ZX-7101A Tablets to Evaluate the Efficacy and Safety in the Treatment of Uncomplicated Influenza in Adolescents
Lead sponsor
Nanjing Zenshine Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2023
Completion date
February 13, 2025
Enrollment
361 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory viral infection